Prosecution Insights
Last updated: April 19, 2026
Application No. 18/571,817

PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES

Non-Final OA §112
Filed
Dec 19, 2023
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Janssen Pharmaceuticals Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
900 granted / 1477 resolved
+0.9% vs TC avg
Strong +44% interview lift
Without
With
+43.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
47 currently pending
Career history
1524
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1477 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application, filed 12/19/2023 is a National Stage entry of PCT/CN2022/101942, International Filing Date: 06/28/2022. PCT/CN2022/101942 claims foreign priority to PCT/CN2021/103244, filed 06/29/2021; and foreign priority to PCT/CN2022/091064, filed 05/06/2022. Certified copies of the foreign priority applications are of record. Status of Claims Claims 1-17 are currently pending. Claims 1-17 were examined and are rejected. Claim Rejections-35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1, 11, and 14 recite “R1 is H, R2 is F and R3 is H or CH3, R1 is H, CH3 or F, R2 is OCH3 and R3 is H and…”. The presence of “and” instead “or” at each recitation for all of R1, R2 and R3 renders the claim indefinite, because it is uncertain which recitations are required or alternative. Claims 2-10, 12-13, and 15-17 are similarly rejected for depending on the above independent claims. Claims 3 and 8 recite “selected from the group comprising…”. This language renders the claim indefinite because “selected from the group” implies selection from a closed, defined list while “comprising” is open-ended and is not exclusive. See MPEP 2173.05(h)(I): A Markush grouping is a closed group of alternatives, i.e., the selection is made from a group "consisting of" (rather than "comprising" or "including") the alternative members. Abbott Labs., 334 F.3d at 1280, 67 USPQ2d at 1196. If a Markush grouping requires a material selected from an open list of alternatives (e.g., selected from the group "comprising" or "consisting essentially of" the recited alternatives), the claim should generally be rejected under 35 U.S.C. 112(b) as indefinite because it is unclear what other alternatives are intended to be encompassed by the claim. The metes and bounds as such aren’t clear. Claims 5 and 7 both recite “preferably”; this renders the claims indefinite, as it is uncertain if the claim scope is limited to the narrower limitations following “preferably”. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: the claimed methods of preparing a compound of formula (I) are not taught or suggested by the prior art. Kesteleyn et. al., WO 2016180696 A1 (cited in the IDS) represents the closest prior art. Kesteleyn teaches processes of preparing compounds of formula (I), wherein formula (I) is structurally the same as formula (I) of the instant claims. While some of the processes taught by Kesteleyn share some of the same reagents as the instant claims, Kesteleyn doesn’t teach or suggest the step of claim 1 wherein 3-methoxy-5-methylsulfonyl-aniline is reacted with a compound of formula (II), reacting a compound of formula (XXVII) with 3-methoxy-5-methylsulfonyl-aniline in the presence of a phase transfer catalyst as recited by instant claim 11, or hydrogenating a compound of formula (III) as recited by instant claim 14. Information Disclosure Statement The IDS filed on 12/19/23 has been considered. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/ Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Dec 19, 2023
Application Filed
Mar 04, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599584
INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594236
Method of Treating Acute Exacerbation of Schizophrenia with Long-Acting Injectable Depot Composition
2y 5m to grant Granted Apr 07, 2026
Patent 12594338
CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12576047
TELOMERASE ACTIVATING COMPOUNDS FOR USE IN FERTILITY AND RELATED APPLICATIONS
2y 5m to grant Granted Mar 17, 2026
Patent 12577209
AMINO ACID COMPOSITIONS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+43.7%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1477 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month